SCHEMBL4646708

SCHEMBL4646708

O=C(O)Cc1ccc(-c2ccc(OCc3ccccc3)c(N3CC(=O)NS3(=O)=O)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.60
RXRA P19793 4/20 0.45
RXRB P28702 4/20 0.45
RXRG P48443 4/20 0.45
ENPP2 Q13822 1/20 0.40
BRD4 O60885 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
ABCC4 O15439 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
PTGS1 P23219 1/20 0.39
HTT P42858 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
PPARD Q03181 1/20 0.38
SMPD1 P17405 1/20 0.37
PTP4A3 O75365 1/20 0.37
PTGER1 P34995 1/20 0.37
PTGER4 P35408 1/20 0.37
PTGER3 P43115 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4643501 0.90 PTPN1 (0.62) PTPN1RXRARXRBRXRGFFAR4
SCHEMBL4644677 0.88 PTPN1 (0.52) PTPN1RXRARXRBRXRGBRD4
SCHEMBL4646595 0.83 PTPN1 (0.53) PTPN1BRD4FFAR4MRGPRX4PTGER1
SCHEMBL629669 0.83 PTPN1 (0.49) PTPN1RXRARXRBRXRGENPP2
SCHEMBL4646366 0.83 PTPN1 (0.61) PTPN1MRGPRX4PTP4A3
SCHEMBL4648546 0.82 PTPN1 (0.57) PTPN1BRD4LMNAPTP4A3
SCHEMBL3920457 0.82 PTPN1 (0.61) PTPN1BRD4MRGPRX4PTP4A3
SCHEMBL4646906 0.82 PTPN1 (0.53) PTPN1FFAR4
SCHEMBL2937609 0.81 PTPN1 (0.58) PTPN1RXRARXRBRXRGENPP2
SCHEMBL4643306 0.80 PTPN1 (0.53) PTPN1HTTPTP4A3PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1960377-A1 l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS Novartis AG (CH) 2008-08-27 EP disclosed
WO-2007067614-A1 l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors PTPRS, IRS1, PTPMT1 PTPN1 10/4885RXRA 4039/4885RXRB 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.